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ABSTRACT 
In New Zealand, approximately 50,000 people or more are infected with 
hepatitis C(HCV), and only 50% or less are currently diagnosed. HCV infection(and 
related complications) is presently the single most common diagnosis leading to 
liver transplantation in New Zealand. With current treatments, HCV infection has a 
high cure rate and the foremost hurdle to eradication is the identification of those 
infected. A blood test to detect HCV antibodies is currently used as the initial test. 
Trained personnel, expensive equipment and repeated appointments are required 
in the current HCV care cascade which increases the number of patients lost to 
follow-up.  
A point-of-care test is a swift testing method that allows individuals to be 
tested, informed of the results and further management started during the same 
visit. The OraQuick HCV point-of-care test has high sensitivity and specificity and is 
validated against traditional EIA testing methods. This test detects HCV antibodies 
and confirmation of active infection is needed with an RNA test after a positive 
antibody test. The study assessed the feasibility of point-of-care HCV testing in a 
general practice setting and at a sexual health clinic in Dunedin, New Zealand and 
aimed to gain insights into participants’ knowledge and experience with the test.  
HCV point-of-care tests were offered to patients aged 45 to 65 years as well 
as anyone at least 18 years old with a risk factor for hepatitis C. Mouth swab 
testing(n=111;50.9%) was used in the initial phase and finger-prick 
testing(n=107;49.1%) later. Volunteers with known hepatitis C were tested as well 
using both testing methods and the tests were positive. Data collected included 
demographics, risk factors for HCV infection and participant experience with the 
testing method. A questionnaire was used to assess knowledge regarding viral 
hepatitis. Data variables have been analysed with significance defined at p < 0.05.  
A total of 218 participants were recruited for the study. The median age was 
29 years(IQR 22 to 46). Fifty six percent(n = 122) of the participants were female. 
All the test via the finger prick method were negative. Fourteen mouth swab tests 
were false positive. One person was detected to have an active HCV infection and 
managed and cured as per guidelines. On knowledge-based questions the study 
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population scored a median of 58.3% (IQR 50 to 75). There were no statistically 
significant differences in percentage of correct answers between participants with 
different levels of education, F(4, 213) = 0.857, p =0.491. A majority of study 
participants (93.6%) reported that they preferred to get their results on the same 
day and that the point-of-care test caused less anxiety(74.8%) compared to a usual 
blood test. There were no complications of administering the rapid point-of-care 
test.  
Point-of-care testing for HCV is feasible and preferred by participants. Only 
one person with active HCV infection was detected. Future studies should take into 
consideration the number of false positives via the mouth swab method of testing in 
this study. Knowledge regarding hepatitis C was low among participants. This study 
has also provided valuable insights into the viability and participants’ experience of 
offering point-of-care testing for HCV in New Zealand. The results form the basis for 
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CHAPTER ONE: INTRODUCTION 
 
1.1 Background of the Study 
 
Over 70 million of the world’s population have chronic hepatitis C infection 
and is at a high risk of developing cirrhosis, liver failure, and hepatocellular 
carcinoma(1, 2). The largest demographic of people who are adversely being 
affected by this condition are individuals with risk factors, have low healthcare 
system engagements and are socioeconomically deprived. With the advancement in 
testing and treatment modalities, such as the increased availability of curative 
antiviral therapy, the World Health Organization (WHO) has a goal to eliminate HCV 
infection as a major global health threat by 2030(1). Other goals in addition to this 
include increasing diagnosis to 90% as well as increasing the fraction of those 
getting treatment to 80% by the year 2030. 
Parental exposure via blood or blood products remains the main mode of 
transmission of hepatitis C(3). This can occur via contaminated injection equipment, 
tattooing, use of contaminated medical equipment and traditional healing practices. 
Transmission can also occur via sexual practices that lead exposure to blood. 
Vertical transmission from mother to child is not common unless the mother has 
high HCV RNA levels. High risk groups include people who work in prisons, 
individuals who use needles to inject drugs, people who have multiple sexual 
partners, new-borns from chronic HCV infected mothers and migrants from HCV 
endemic regions(4, 5). The initial infection of HCV is relatively asymptomatic or 
mild in 70-90% of the cases. Untreated, 50-80% of the people infected will develop 
a chronic disease and eventually liver cirrhosis in 50% and liver cancer in up to 5% 
of the infected people after approximately 20-30 years(6, 7). According to WHO 
350,000 to 500,000 patients die each year from hepatitis C-related liver 
diseases(8).  
According to the New Zealand Ministry of Health, there are more than 50,000 
people in the country with chronic hepatitis C infection(9). However, only 50% of 
the estimated infected people have currently been diagnosed. The condition can 
 10 
 
remain asymptomatic for decades. In cases where the diagnosis is made early, 
treatment with a high chance of success can be initiated to avoid or delay the onset 
of complications related to the disease(6, 10). The development and availability of 
the oral direct-acting antiviral (DAA) therapies that can cure HCV infections within a 
period of two to three months have drastically revolutionised the HCV care 
approach and increased the calls for the elimination of this virus as a major global 
health problem(1, 11). It is estimated that the DAA offers a cure rate of 95% or more 
with little or no side-effects with a finite duration for the treatment of weeks(11). It 
is a contrast from the interferon-based therapies that were used in the past as they 
had poorer outcomes, side-effect problems, which led to a majority of individuals 
who had been diagnosed with the condition to opt not of treatment.  
Until 2016, treatment uptake for hepatitis C was low. In New Zealand, less 
than 10% had access to treatment of the condition by 2014. According to the 2017 
Pharmac report, in New Zealand, 2,000 people had been treated with the new 
DAAs(12). However, achieving the objective that has been set by the WHO requires 
that 90% of the with HCV be diagnosed, and 80% of the diagnosed people treated by 
2030(8). The achievement of these targets is highly probable in countries that offer 
unrestricted access to DAA therapy in addition to programs that actively seek to 
raise awareness and diagnose those with chronic hepatitis C infection.  
The current HCV treatment cascade involves multiple steps and 
engagements with health services including initial assessment, requesting screening 
antibody testing, confirmatory testing, assessment of liver fibrosis, initiation of 
treatment and follow-up(13, 14). There are multiple steps and visits needed which 
increase the chance of a patient being lost to follow-up. A rapid point-of-care test for 
hepatitis C allows for testing at the initial visit with results available at the same 
visit. Moreover the method of a rapid point-of-care test does not involve blood 
draws via venepuncture which may make is more acceptable. This has the potential 
to drastically improve health care delivery as well as engagement and linkage to 




1.2  Aims and significance of the project 
 
The objectives of the study were:  
a) Assess the feasibility of point-of-care HCV testing in a general practice setting 
in New Zealand.  
b) Gain insights into the experience of the participants with the test.  
c) Assess the knowledge of the participants regarding prevalence, transmission 
and treatment of hepatitis C. 
d) Assess patient uptake of further investigations after a positive point-of-care 
HCV test.  
 
Due to recent advances in pharmacology and therapeutics, chronic hepatitis 
C is now a disease with a high rate of cure. The primary hurdle to eradication is the 
identification of those infected and linkage to care at an early stage before cirrhosis, 
liver failure and associated complications develop. The study provides valuable 
information about the feasibility of rapid-point-of-care testing for hepatitis C in New 
Zealand as well as the experience and knowledge of the participants undergoing 
testing.  
This study provides useful data to guide implementation of rapid point-of-
care testing of hepatitis C in selected settings in New Zealand as a strategy to boost 
the identification of those with hepatitis C and link them into the care cascade. Early 
identification and treatment of chronic hepatitis C can prevent liver fibrosis, 
cirrhosis and associated complications which are known to place a significant 




CHAPTER TWO: LITERATURE REVIEW 
 
2.1 The Origins and Discovery of Hepatitis C 
 
Viral hepatitis infections were originally recognized by jaundice or other 
typical symptoms of the infection in the 1960s(15). Two types were recognized at 
the time based on exposure and incubation periods – type A or ‘infectious’ hepatitis 
and type B or ‘serum’ hepatitis(16). Hepatitis A had a short incubation period and a 
faecal-oral route of transmission while patients with hepatitis B had a long 
incubation period and percutaneous blood exposure. Studies initiated to 
understand the epidemiology and investigate prophylaxis of transfusion-related 
hepatitis soon led to the discovery of hepatitis C virus (HCV)(17, 18). These studies 
expanded the diagnosis of hepatitis as participants had aminotransferase levels 
checked frequently and thus diagnosis was not just limited to clinical jaundice and 
other symptoms. Blood samples of participants were stored for possible future 
research which would soon to become invaluable in future after tests for hepatitis C 
were available(19).  
 
After the availability of serologic methods of diagnosis, the existence of a 
third hepatitis virus was discovered when it was identified that a majority of the 
cases of the transfusion-associated hepatitis were not from hepatitis-A or hepatitis-
B virus infections(17, 20). This as-yet unknown virus was called non-A non-B 
hepatitis (NANBH). Researchers noted that there was scientific evidence that 
showed that the blood-borne NANBH agent could be a small, enveloped virus that 
could be transmissible to chimpanzees(21). One of the obstacles for identifying this 
‘new’ virus at that time was difficulty in identifying the specific viral antibodies and 
antigens. It was thought that the reason was insufficient concentrations of the viral 
antigen in NANBH infections(22). Researchers managed to clone and sequence the 
genome of the HCV using the high-titre samples that had been collected from a 




It was noted that the HCV infection led to the development of acute and 
chronic hepatitis and liver cancer at later stages of the people who had this 
virus(23). It is essential to point out that, after the identification of HCV, it was 
determined that this virus was the cause of 90% of the NANBH diagnoses in the 
United States alone(24). Further studies would find multiple genotypes of this virus 
with geographical distribution as well as multiple subtypes within each 
genotype(25, 26). Genetically diverse variations of HCV could have been around in 
South East Asia and sub-Saharan Africa for hundreds or years and this could 
indicate the possible origin of HCV.  
 
The more recent pandemic in the last century seems to be related to 
relatively modern medical practises (intramuscular injections, intravenous 
injections, venepuncture for blood tests,  surgical and other invasive procedures) 
compared to previous centuries as well as due to injecting drug use(27, 28). 
Epidemiological and phylogenetic reconstructions have revealed that the genotypes 
in United States of America can be traced back to Japan(29, 30). These were likely 
introduced in Japan at the end of the 19th century. Modern risk factors like 
parenteral/intramuscular injections, unsafe medical, surgical and dental procedures 
as well as injecting drug use may have resulted in the spread of HCV in Japan. 
Spread to the US likely occurred as a result of injecting drug use among soldiers 
during World War II (31). Hence the increase in cases in the last century likely 
occurred initially during the 1940s and 1950s but unavailability of samples for 
testing and the lack of serological tests at the time make it difficult to effectively 
prove this.  
 
After World War II and until the identification of the virus and 
implementation of HCV testing before blood transfusions in the 1990s, transfusion 
related transmission and injecting drug use was the main cause of the spread of 
hepatitis C; although unsafe medical practises likely contributed to increased spread 




2.2 The Pathogenesis of Hepatitis C 
 
Hepatitis C virus is an enveloped RNA virus, which belongs to the genus 
Hepacivirus of the family Flaviviridae(33). The HCV genome codes for a long protein 
that is modified and processed during and after translation into multiple structural 
and non-structural proteins(34). The envelope proteins are structural proteins that 
play an important role in viral entry into cells. The RNA polymerase of the HCV virus 
lacks proof-reading ability and hence this results in increased heterogeneity and the 
development of ‘quasispecies’ within the same genotype of the virus(35). Although 
it replicates in the cytoplasm of hepatocytes, it is a non-cytopathic virus. The high 
rate of infection among individuals is a result of the rapid production of the virus 
and continuous cell-to-cell spread(36).  
 
HCV can evade innate immunity by counteracting retinoic-acid inducible 
gene-1 (RIG-1) pathway which plays a major role in inducing expression of 
interferon alpha and beta which are important in inducing cells to resist infection, 
activate natural killer cells inhibit viral replication and enhance adaptive 
immunity(37). In addition to that, a lack of vigorous T-cell immune response to the 
HCV antigens is considered to be one of the causes of the high rate of HCV infections 
that have been reported globally(38). HCV turnover rate is estimated to range 
between 1010 to 1012 virions per day(39). The reasons why the viral genome 
continues to mutate constantly are because of the fast viral replication as well as the 
lack of proofreading by the viral RNA polymerase. Studies have identified seven 
HCV genotypes, which are numbered 1 to 7, and within the genotypes there are 
more than 50 known subtypes of this virus(35, 40).  
 
HCV causes hepatocyte necrosis and liver damage via a number of 
mechanisms which are immune mediated and metabolic(41). Immune mediated 
damage can occur via the innate as well as the adaptive immune system. Metabolic 
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damage includes oxidative stress, insulin resistance and hepatic steatosis. HCV core 
protein as well as non-structural proteins (NS5A and NS3) directly causes oxidative 
stress(42). NS3 also sets off reactive oxygen species by activating NADPH oxidase in 
phagocytes. HCV infection leads to hepatic inflammation, apoptosis and fibrosis via 
multiple mechanisms(43).  
 
2.3 The Natural History of Hepatitis C Infection 
 
The initial infection of HCV is relatively asymptomatic or mild in 70-90% of 
the cases. 50-80% of the people infected will develop a chronic disease and this at 
later stages of their lives and can eventually lead to the development of liver 
cirrhosis in 50% and liver cancer in up to 5% of the infected people after 
approximately 20-30 years(6, 44, 45). According to WHO, worldwide approximately 
350,000 to 500,000 people die each year from hepatitis C-related liver disease and 
associated complications(8).  
 
The available data on the progression of chronic HCV indicates that the 
stages of the disease from acute HCV infection to cirrhosis or hepatocellular 
carcinoma (HCC) can take twenty years after the initial infection(46-48). Other 
studies suggest that diseases such as cirrhosis, end-stage liver disease (ESLD) and 
HCC are highly likely to emerge after 30-40 years after the initial infection of an 
individual. Individuals who have chronic HCV are the ones who have HCV in their 
blood system for more than six months after the onset of acute infection. It is 
estimated that approximately 55-85% of the patients who have been diagnosed 
with acute HCV will transition to chronic HCV diagnosis(46). It is essential to point 
out that once the infection transitions from the acute to chronic stage, then 
spontaneous resolution is rare. A noted chronic HCV can lead to patients developing 
fibrosis and later on cirrhosis, hepatocellular carcinoma and end-stage liver 
disease(44, 49, 50). Approximately 20-30% of the patients that have been 
diagnosed with chronic HCV will progress to liver cirrhosis(6). However this 
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inference can be variable and depending on the method used by different 
researchers to define the natural clinical history of hepatitis C infection.  
 
In an analysis of multiple studies that were conducted to estimate the 
progression from chronic HCV to cirrhosis in specialist liver clinics, community 
cohorts and post-transfusion cohorts — the estimation of the progression from 
chronic HCV to cirrhosis after 20 years was variable(51). In the post-transfusion 
studies progression to cirrhosis was determined to be 24%; 22% in specialist liver 
clinics; 7% in community cohorts; and 4% in blood donors. Factors such as selection 
/ recall bias and short duration during the follow-up have been cited as the 
probable reasons of the differences in the estimated rates(6, 52).  
 
Advanced stages of liver fibrosis are considered to be a precursor of cirrhosis 
and, therefore can be considered as an indicator of the course of this disease(44, 
53). Individuals with chronic HCV who have advanced liver fibrosis with non-
invasive tests are highly likely to be diagnosed with cirrhosis, may require liver 
transplantation at the later stages of their lives or experience liver-related 
complications and deaths(44, 54). Therefore, the degree of progression of liver 
fibrosis plays an important role determining the outcome of chronic HCV infection. 
The progression of fibrosis can be affected by multiple other factors independent of 
chronic HCV infection(44, 54, 55). Monitoring the progress of liver fibrosis can be an 
effective way of predicting the outcome of chronic HCV infection. 
 
Studies with liver biopsy data provide a period of approximately 30 years 
from chronic HCV to the development of liver cirrhosis(56). However, the 
progression of fibrosis varies in different patients depending of multiple factors 
which may include both alcoholic as well as non-alcoholic fatty liver disease(44, 54). 
There are limitations of assessment of liver fibrosis by non-invasive methods. It has 
been reported that the progression of chronic hepatitis C infection to liver cirrhosis 
can take 30 to 40 years after conducting paired liver biopsy studies(57). The 
development of advanced liver fibrosis and cirrhosis in patients with chronic HCV 
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infection represents a critical point in the course of disease. The reason for this is 
that these patients are at a high risk of developing complications of liver disease 
including ascites, bacterial peritonitis, haemorrhage from varices and hepatic 
encephalopathy(58). These conditions increase the likelihood of liver 
transplantation or risk death due to complications. The data on the subject of the 
course of hepatitis C infection after the development of cirrhosis has been gathered 
mainly from studies that have been conducted in tertiary referral centres. The 
survival of the patients who have been diagnosed with compensated liver cirrhosis 
in the short-and medium-term has been determined to be good(58, 59). For 
instance, the five-year survival rate in patients with liver cirrhosis is between 85-
91% and 10-year survival rate has been determined to be approximately 60-79%.  
 
The HALT-C trial has provided crucial data regarding the natural history of 
patients that have been diagnosed with advanced fibrosis and cirrhosis. The results 
have shown that the three most common clinical occurrences in patients with liver 
fibrosis as well as those with established cirrhosis were hepatocellular carcinoma, 
abdominal ascites and death (due to all causes)(60, 61).  Planas et al. (2004) 
conducted a study with 200 patients who had been diagnosed with HCV-related 
cirrhosis and admitted with first episode of decompensation. These patients were 
without any known HCC. In a follow-up of three years, it was found that HCC 
developed in 33 (16.5%) of the patients and death occurred in 85 (42.5%). It was 
recognized that the chances of survival after their first presentation with 
decompensated cirrhosis were 82% and 51% at one and five years, 
respectively(59). Survival was low if the patients developed hepatic encephalopathy 
or abdominal ascites as the first hepatic decompensation.  
 
Morbidity and mortality rates that have been caused by hepatitis C infections 
have been increasing (62). The WHO report noted that east and south Asia had the 
highest rates of mortality from hepatitis C infections (52% of the total number of 
deaths). Also, it was noted that unlike HIV infections, 58% of the hepatitis and 
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associated liver disease related deaths reported globally have occurred in the 
upper-middle income countries.  
 
Untreated, approximately 25% of patients with chronic HCV will develop 
cirrhosis with associated complications and morbidity as well as increased use of 
healthcare resources(44). The progression of those with cirrhosis to the 
development of hepatocellular carcinoma or liver failure is approximately 10% per 
year. Chronic HCV infection contributes to 27% of cirrhosis and 25% of 
hepatocellular carcinoma(63). Cirrhosis due to HCV with or without hepatocellular 
carcinoma is currently the single most extensive diagnosis leading to liver 
transplantation in New Zealand with more than a quarter (28%) of the liver 
transplants per year(64). The rate of organ donation in New Zealand is relatively 
low at 11.6 per 1 million population per year with no substantial improvement over 
the last several years(64). Identifying and treating patients with HCV infection 
would lead to the prevention of cirrhosis and associated complications and 
potentially increase the relative availability of deceased donor livers for transplants 
for other patients in need.  
 
2.4 Current Prevalence Levels 
 
The WHO has estimated that more than 70 million people worldwide have 
chronic hepatitis C which is an estimated one percent of the world’s population(1, 
2). These patients are at a high risk of developing cirrhosis, liver failure, and 
hepatocellular carcinoma. HCV infection leads to significant morbidity and 
mortality. There is significant economic and resource burden on healthcare systems 
as a result of chronic HCV infection and its associated complications(65). In 2015, 
the worldwide incidence hepatitis C was estimated to be 23.7 per 100,000 
population – indicating 1.75 million estimated new HCV infections. The largest 
demographic of people affected are those with relatively low healthcare system 
engagement and are socioeconomically deprived(63). With the advancement in 
diagnostics and therapeutics, the Global Health Sector Strategy to eliminate 
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hepatitis C as a major health burden by 2030 was approved by the 69th World 
Health Assembly in 2016(66). The WHO has introduced global targets for 2030 
regarding the prevention and treatment of hepatitis C infection including “a 90% 
reduction in new cases of hepatitis C” and “treatment of 80% of eligible people with 
chronic hepatitis C infections”.  
 
There are more than 50,000 people in New Zealand infected with hepatitis 
C(9). In addition there are approximately 1000 new hepatitis C infections in New 
Zealand each year(13). Only 50% of the estimated number of people with chronic 
hepatitis C in New Zealand have currently been diagnosed. Similarly, research from 
Canada shows that only 56% of those infected with hepatitis C are aware of their 
positive HCV status(67). In the United States, only about 50% of persons with 
hepatitis C have been diagnosed(68). The reported prevalence of chronic hepatitis C 
varies depending on the groups assessed. The prevalence of hepatitis C antibody 
positivity has been reported to be 0.3% in a prevalence study done in Christchurch, 
New Zealand(69). This was a community prevalence study done from an electoral 
role. Among people living in Dunedin aged forty to fifty-nine years, the prevalence of 
hepatitis C antibodies has been reported to be 4.01%(70). The prevalence of 
hepatitis C in New Zealand is estimated to be highest in the 45 to 65 years old age 
group at approximately 3.0% and 4.5% in females and males respectively(71).  Data 
from New Zealand reported a prevalence of chronic hepatitis C infection in the 
range of 17.8 to 43.5% in adults with risk factors(72, 73). 
 
It has been noted that there are more than 350,000 deaths as a result of 
chronic HCV, which are mainly caused by liver cirrhosis, associated complications 
and hepatocellular carcinoma (HCC)(1, 74). Overall 27% of cirrhosis and 25% of 
HCC cases that are reported worldwide could be attributed to HCV infection(74). In 
addition the rates in some countries are highly substantial than in others. For 
instance, in Japan, up to 90% of all the reported HCC cases were caused by HCV 
infection. The data regarding HCV infection varies by country and region, hence the 
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real data and burden of disease cannot be accurately recognized because of limited 
data in a majority of the countries(74). 
 
With respect to hepatitis C infection it has been noted  that the most affected 
regions globally are the WHO Eastern Mediterranean and WHO European regions, 
which have a prevalence rate of 2.3% and 1.5% respectively(1). In a majority of the 
countries, new HCV infections can be attributed to the use of injections and other 
utensils during drug use and it is therefore mainly concentrated among people who 
inject drugs than any other socio-demographic group in the region. However, in 
countries where there have been no or limited infection control practices, HCV 
infections are widely distributed in the general population. It is also important to 
note that although there are multiple strains or genotypes of the HCV virus and that 
their distribution varies from one region to another, in a majority of the countries, 
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Figure 1: Current HCV care cascade and steps leading to treatment; points of potential loss to follow-up due to patient factors 
are indicated by red triangles. HCV: Hepatitis C. PCR: Polymerase chain reaction. 
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2.5 Testing and Treatment of Hepatitis C 
 
The current HCV care cascade involves multiple steps before initiation of 
treatment (Figure 1). This includes multiple engagements with health care 
services(13, 14). The initial test for hepatitis C infection is testing for hepatitis C 
antibody via venepuncture. The use of an enzyme immunoassay (EIA) to detect HCV 
antibodies - and if positive - followed by testing for HCV RNA is the method of 
choice for diagnosing HCV infection(13, 76). These diagnostic tests require trained 
personnel, expensive equipment and high running costs. The HCV antibody test and 
the HCV RNA test are done at separate visits in the current treatment cascade of 
HCV. Positivity of HCV antibody test can be due to HCV infection or due to previous 
exposure with spontaneous recovery. It will also be positive in previously treated 
and cured hepatitis C patients. Hence further HCV RNA testing is needed to confirm 
active infection if the antibody test is positive. Additionally in almost all clinical 
settings, the blood drawn via venepuncture for the antibody test cannot be used to 
automatically test for HCV RNA (if antibody test is positive) due to different 
collection tube and processing requirements as well as time limitations on when the 
RNA testing can be done(77). ‘Reflex testing’ for HCV RNA after a positive antibody 
test means running the test automatically on the available blood sample if the 
antibody test is positive. This has been tried in some central laboratories 
internationally but has its limitations(77, 78).  Hence, a second visit to the 
phlebotomist is needed to confirm active infection.  
 
Testing for hepatitis C can be requested and recommended for a patient for a 
number of reasons including a history of risk factors, investigation of abnormal liver 
enzymes or symptoms suggestive of viral hepatitis. Result availability after antibody 
testing and further communication of the result can take time. This can lead to 
another appointment with a health care worker for counseling. Further 
confirmatory testing with HCV RNA is also required to establish the diagnosis of a 
chronic infection as antibody can be positive in those who have spontaneously 
cleared a previous infection. Furthermore, some patients will need assessment of 
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liver fibrosis with a fibroscan or shearwave elastography which is available in 
tertiary care centers and in some cases at outreach clinics(13). There are multiple 
steps and visits needed which increase the chance of a patient being lost to follow-
up(77, 79). This process can be tedious, time-consuming, involve multiple visits and 
is not promising in encouraging increased testing and identification of more than 
half of those infected with HCV who don’t know their status of infection. Moreover, 
the process of providing a blood sample may dissuade patients from testing. Anxiety 
which is compounded by the waiting time for a result after a blood test is another 
factor that may prevent patients from being tested(79). It has been shown that a 
large number of patients are lost to follow-up at multiple steps in the current care 
cascade after an initial positive antibody test for hepatitis C (Figure 2)(80).  
 
 
Figure 2: Proportion of patients lost to follow-up at various levels of HCV care 
cascade. High proportions of patients are lost to follow-up after the initial positive 
antibody test and then after a positive RNA test. Reprinted with permission from 
Mera at al. 2016(80). 
 
A point-of-care test is a swift testing method that allows individuals to be 
tested and informed of the results during the same visit(81). These investigations 
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occur in the setting where the patient is receiving care such as at the general 
practitioner’s or nurse’s clinic and do not involve sending specimens to a laboratory 
for testing with subsequent waiting for a result to be communicated to the 
healthcare professional. Point-of-care tests can be administered and inferred by 
doctors and nurses and even non-medical staff like health-care assistants(81). The 
method of a rapid point-of-care test may not involve blood draws via venepuncture 
which may make it more acceptable. This has the potential to drastically improve 
health care delivery as well as engagement and linkage to care for patients with 
chronic hepatitis C. It has been shown that using a point-of-care test led to an 
increase in the entry points and also avoided delays in HCV care(77). The use of 
point-of-care tests for the detection of HCV antibodies can be used and implemented 
in multiple settings including emergency departments, prisons and needle exchange 
programs for people who inject intravenous drugs (PWID)(82-85).  
                            
Several modalities of point-of-care tests can be used for HCV testing such as a 
serum, plasma, whole blood or oral fluid(86). Testing for HCV infection with a swab 
of oral fluid is the easiest to administer both for the provider and the patient. One 
such test is the OraQuick testing kit. The sensitivity of OraQuick (oral liquid) test is 
95.9 to 98% and specificity of 99% in a meta-analysis and this proved to have the 
highest sensitivity and specificity among the compared tests using oral fluid for 
testing(87). This is an easy to administer test both for the patient and the provider. 
Test results are available in 20 to 30 minutes. Settings, where it can be offered, 
could include GP practices, nurse-led clinics, sexual health clinics, and remote 
settings by visiting health care workers. Further confirmation of active infection in 
case of a positive HCV antibody point-of-care test requires an HCV RNA test by 
venepuncture. 
 
Point-of-care tests are favored by healthcare providers as well for various 
reasons with a study showing 99% of providers preferring the point-of-care 
test(88). Advantages include a high number of tests being done in a limited period, 
ease of administration, fewer or no needle-stick injuries, one visit for test and 
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results, which translates into increased testing for confirmatory tests and referral 
for treatment; this in-turn improves patients’ adherence with work-up and 
management.  
   
With the introduction of new direct-acting antiviral (DAA) treatments – 
which are highly effective – there is a real possibility of eliminating HCV as a major 
health problem in New Zealand(89, 90). Previously the funded DAA in New Zealand 
was a combination of paritaprevir, ritonavir, ombitasvir, dasabuvir + ribavirin for a 
duration of 8 to 12 weeks depending on patient factors. This was not ideal as it was 
only used and approved for treatment of genotype 1 of hepatitis C virus. A 
pangenotypic DAA which is a combination of ledipasvir and sofosbuvir is also 
available but only for patients who fulfil certain criteria(91). Currently another 
pangenotypic DAA is funded for all patients with hepatitis C infection who qualify 
for publically funded healthcare in New Zealand. This is a combination of 
glecaprevir (NS3/4A protease iinhibitor) and pibrentasvir (NS5A inhibitor). The 
duration of treatment is 8 to 16 weeks depending on patient factors with cure rates 
of 96% to 100%. However, one of the key challenges in treating patients with 
chronic HCV is identifying those who are infected which in turn is dependent on 
feasible and practical testing; in addition to linkage to healthcare. Improvements in 
testing are crucial in identifying those with HCV infection so they can become aware 
of their status of disease and be offered curative treatment. One such innovation to 
improve testing and detection is the rapid point-of-care test for hepatitis C virus 
antibodies.  
 
While testing is a critical step in initiating the process of diagnosis, it is also 
crucial that patients are linked to treatment providers or specialty care as indicated 
upon diagnosis. In New Zealand, patients with confirmatory HCV testing are 
recommended to undergo assessment of liver fibrosis/cirrhosis with either an APRI 
score or with other means (shear wave elastography or Fibroscan)(13). Treatment 
can be commenced, monitored and completed by the general practitioner if there is 
no indication of advanced fibrosis or cirrhosis. Patients are assessed and treated in 
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tertiary or specialty care in case of cirrhosis or other factors affecting treatment like 
those co-infected with human immunodeficiency virus. A point-of-care test can 
increase the rates of adherence to further investigations and management 
compared to traditional testing methods. A previous study has shown that people 
who chose the rapid point-of-care HCV testing were significantly more likely to be 
connected to specialty care than those who chose the usual laboratory testing 
(93.8% compared with 18.2%)(92). A point-of-care test for hepatitis C can 
significantly streamline the testing process and can decrease the number of people 
lost to follow-up(93-96). This will eventually increase the number of people who 
offered treatment with a high chance of cure.  
 
The uptake of HCV screening tests at GP clinics ranges from 27.8% to 82.5% 
with most of the studies done in France(96). Since the point-of-care tests for HCV 
infection can be conducted as well as inferred outside of hospitals and in remote 
areas, it may also increase the number of people tested(92, 97). This is especially 
important for populations who may not have equal access to health care or their 
access is impaired by the cost of attending multiple appointments for tests and 





CHAPTER THREE: METHODOLOGY 
3.1 Ethical Approval 
Ethical approval was obtained from the University of Otago Ethics 
Committee (HE18/009). Written informed consent was obtained from all 
participants in accordance with the Declaration of Helsinki. 
 
3.2 Recruitment Methodology 
 
Information about the study was given to prospective participants attending 
three general practice settings and one sexual health clinic in Dunedin, New 
Zealand. Meetings were held with administrators/leaders of the study localities and 
locality approval was obtained. Information regarding the study was given and all 
queries were answered. Recruitment was done over a period of twelve months from 
November 2018 to October 2019. Recruitment was only scheduled for days when 
there was a clinic room available for the investigators to ensure confidentiality. 
Convenience sampling was used in this study. Study information was given to all 
clinic attendees during recruitment sessions at reception upon arrival or in the 
waiting area by clinic administrative staff or by the investigators. Prospective 
participants were enrolled if they met the inclusion criteria.  
 
3.3 Inclusion Criteria 
 
Inclusion criteria for participants were as follows: 
1. All individuals aged 45 to 65 years (inclusive) regardless of risk factors. 
2. All adults who report any of the following risk factor(s): 
a. Any history of intravenous drug use.  
b. Born to an HCV positive mother.  
c. Have human immunodeficiency virus (HIV) infection. 
d. Have received blood products or organ(s) before 1993.  
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e. Have ever been on haemodialysis. 
f. Have received blood products or organs overseas (excluding Canada, United 
States, Western Europe and Australia).  
g. Have had any surgical or dental procedures overseas (excluding Canada, 
United States, Western Europe and Australia).  
h. Have ever been incarcerated.  
i. Have ever had any tattoo, piercing or used piercing equipment that may have 
been unsterilized (as perceived by the study participant depending on 
observed practices).  
j. Have ever visited a barber, beauty therapist/nail salon in unsterile 
conditions.  
k. Have a sexual partner with known hepatitis C. 
 
3.4 Exclusion Criteria 
Exclusion criteria for participants were as follows: 
1. Aged under 18 years old 
2. Previous diagnosis of hepatitis C infection or previous positive test for HCV 
3. Unwilling or unable to give written informed consent 
 
3.5 Testing for Hepatitis C 
 
All investigators were trained in performing the test. After written informed 
consent, study participants had rapid point-of-care testing for hepatitis C antibody 
performed in a private and confidential setting at the study localities. The OraQuick 
test from OraSure Technologies was used(98). In the initial stage of the study, HCV 
testing was done using a mouth swab and later, finger-prick testing (done using the 
same test kit as above) for results, and participant experiences comparisons. The 
test takes approximately 20 minutes to generate a result. The workflow 
methodology is summarized in figure 3. A wait period of 15 minutes is required for 
the mouth swab test after food and beverage; and a wait period of 30 minutes after 
the use of oral care products. At intervals during data collection and testing, five 
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volunteers with known hepatitis C infection were also tested with both the mouth 
swab and finger-prick method of point-of-care testing to ensure validity of the batch 
of testing kits. All of these tests were positive as expected.  
 
 
Figure 3: Summary of study methodology before and after administration of 







3.6 Data Collection 
 
De-identified data was collected using a questionnaire. Each participant filled 
a questionnaire (Appendix A), which collected information regarding demographics, 
risk factors for HCV infection, experience with any previous HCV tests as well as 
questions about their experience with the point-of-care test. These responses and 
clinical information collected by staff were also used. The investigator was available 
in case of any queries regarding filling the questionnaires. Data from questionnaires 
and test results was entered into Microsoft Excel and Statistical Package for Social 
Services software for analysis. 
 
3.7 Data Analysis 
 
Clinical and socio-demographic variables have been analyzed using chi-
square and t-tests where appropriate with significance defined at p < 0.05. An x2 
test for independence was used to determine if there were any association between 
tested knowledge levels, education, ethnicity and exhibited risk factors. Chi square 
and t-test were used to explore the associations during data analysis. One-way 
ANOVA with Tukey HSD post hoc test (for the level of education) was used to 







CHAPTER FOUR:  RESULTS  
 
4.1 Patient Demographic Data 
 
A total of 218 participants were recruited for the study. The frequency of 
recruitment days was dependant on the availability of a clinic room at the study 
localities. The mean age was 35.2 years with a standard deviation of 15.96. The 
median age was 29 years with an interquartile range of 22 to 46. Fifty six percent (n 
= 122) of the participants were female and 44% were male (n = 96). One hundred 
and fifty-one (69.3%) of the participants identified themselves as of New Zealand 
European ethnicity.  Demographic characteristics of participants are given in table 
1. Majority of the study participants were less than 40 years old. Age distribution of 
the participants is illustrated in figure 4. 
        
      Table 1: Demographic characteristics of participants.  
Characteristics of Participants %  (n) 
Sex, male 44%      (n = 96) 
Mean age in years (IQR)  35.2      (22 – 46) 
Ethnicity  
     New Zealand European 69.3%  (n = 151) 
     Maori 10.6%  (n = 23) 
     Other European 16.1%   (n = 35) 
     Asian  3.2%    (n = 7) 
     Other 0.9%    (n = 2) 
Education  
    Secondary 12.8%   (n = 28) 
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    Tertiary 33.5%   (n = 73) 
    Undergraduate 43.5%   (n = 94) 





Figure 4: Age distribution histogram of the study participants.  
 
4.1.1 Participants’ Level of Education 
Majority of the participants (43.5%; n = 94) reported having completed an 
undergraduate degree.  Figure 5 illustrated the distribution of participants 
according to the reported level of education. More than sixty percent (60.4%) of 
those reporting having undergraduate education were females. Table 2 shows the 














Table 2: Level of education of male and female study participants.  
 
 
Education Secondary Tertiary Undergraduate  Graduate 
Sex Male 14 32 37 13 
Female 13 40 57 10 








4.1.2 Participants’ Engagement with General Practitioner 
 
 Data regarding the engagement of study participants with their general 
practitioner was collected. Majority (41.3%) of the study participants visited their 
general practitioner on a six monthly basis. Thirty-nine (17.9%) participants 
reported visiting their general practitioner rarely. Majority (n = 30) of these were 
less than 45 years old. Two participants reported visiting their general practitioner 
only five yearly and both were less than 45 years old. Data regarding general 
practitioner visits is given in table 3.  
 
Table 3: Frequency of visits to their general practitioner as reported by study 
participants according to age categories.   
 
Age  Age less than 45 
years, n (%) 
45 to 65 
years, n (%) 
More than 65 
years, n (%) 
Total,  
n (%) 
GP Visits          
    Weekly 4 (2.5%) 0 (0%) 0 (0%) 4 (1.8%)     
    Monthly 34 (21%) 7 (17.1%) 5 (33.3%) 46 (21.1%)   
    Six   monthly 64 (39.5%) 18 (43.9%) 8 (53.3%) 90 (41.3%)   
    Yearly 28 (17.3%) 7 (17.1%) 2 (13.3%) 37 (17%)      
    Five yearly 2 (1.2%) 0 (0%) 0 (0%) 2 (0.9%)    
    Rarely 30 (18.5%) 9 (22%) 0 (0%) 39 (17.9%)   








4.2 Results of HCV Point-of-Care Test 
The HCV point-of-care test done via finger-prick was negative in all 107 
participants tested by this method. Fifteen participants had positive test via the 
mouth swab method of testing. These participants went on to have venepuncture 
for ELISA antibody testing and HCV RNA by PCR. The ELISA antibody test and HCV 
RNA tests were negative in all but one of these participants with a positive mouth 
swab test. Hence 14 out of 15 positive mouth swab tests were false positive. Six of 
these participants were male and 8 were females. If the negative tests via mouth 
swab are assumed to be true negatives, the specificity via the mouth swab method 
comes out to be 87.3%.  
 One male participant with positive mouth swab point-of-care test had 
positive serum antibody test as well as detectable HCV RNA. Thus one participant in 
the study had an active HCV infection detected. He reported a previous history of IV 
drug use. He was managed according to the NZSG guidelines and treated with a 
combination of glecaprevir and pibrentasvir. HCV RNA testing at week 12 after 
completion of treatment showed sustained virologic response (SVR). The effect of 
point-of-care testing on linkage to care could not be assessed as only one participant 
was detected to have an active HCV infection. This participant followed through 
with treatment leading to HCV cure. 
 
4.3 Risk Factors of Hepatitis C among Study Participants 
The most common risk factor reported was a history of getting service at a nail 
salon or barber which the participants deemed to be unhygienic or unsterile. One 
hundred and seven participants (49.1%) reported having this risk factor. The 
second most common risk factor for hepatitis C infection among study participants 
was having a history of a tattoo or piercing with possible unsterilized equipment. A 
total of 79 study participants (36.2%) reported having this risk factor with majority 
(41.3%) of them being less than 45 years old. Forty four participants (20.2%) 
reported having administered first aid to an unknown bleeding person and eleven 
(5%) reported a history of intravenous drug use. Table 4 details the prevalence of 
risk factors for hepatitis C infection according to the age categories of the 
participants.  
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Table 4: Risk factors for hepatitis C infection according to the age categories of 
the participants.  
 Less than 
45 years. 
% (n = 
162) 
45 to 65 
years. 
% (n = 41) 
More than 
65 years. 
% (n = 15) 
Total  
% (n = 218) 
IV drug use 5.6 % (9) 4.9% (2) 0 % (0) 5% (11) 
HCV antibody positive 
mother 
0.6 % (1) 0 % (0) 0 % (0) 0.5% (1) 
HIV Infection 0.6 % (1) 0 % (0) 0 % (0) 0.5% (1) 
Blood/organ 
recipient before 1990 
1.9 % (3) 4.9 % (2) 20 % (3) 3.7% (8) 
Haemodialysis 0.6 % (1) 0 % (0) 0 % (0) 0.5% (1) 
Blood/organ 
recipient overseas* 
0.6 % (1) 2.4 % (1) 0 % (0) 0.9% (2) 
Procedure overseas* 11.1 % (18) 17.1% (7) 6.7 % (1) 11.9% (26) 




41.3 % (67) 16.7 % (7) 33.3 % (5) 36.2% (79) 
Barber/nail salon 55.6 % (90) 26.8 % (11) 40 % (6) 49.1% (107) 
Needle stick injury 6.8 % (11) 24.4 % (10) 6.7 % (1) 10.1% (22) 
Administered first aid 
to an unknown 
bleeding person 
17.9 % (29) 34.1 % (14) 6.7 % (1) 20.2% (44) 
*Blood/organ recipient and procedures done overseas excluding Canada, United 




 Fifty-eight out of 151 participants of New Zealand European ethnicity 
(38.7% within ethnicity) reported getting a tattoo or piercing with possible 
unsterilized equipment. More than half of participants of Maori ethnicity (13 out of 
23) in this study reported getting a tattoo or piercing with possible unsterilized 
equipment. A chi-square test for association was conducted between those of Māori 
ethnicity and a history of getting a tattoo or piercing with unsterilized equipment. 
All expected cell frequencies were greater than five. There was a statistically 
significant association between Māori ethnicity and history of getting a tattoo or 
piercing with unsterilized equipment, χ2(1) = 4.497, p = 0.034.  
 
A sizable proportion of study participants of all ethnicities reported getting 
service at a barber or nail salon under unhygienic/unsterile conditions. The number 
of participants identifying themselves of Asian ethnicity was small (seven), however 
six of them reported getting service at a barber or nail salon under 
unhygienic/unsterile conditions. Table 5 details the prevalence of risk factors for 
hepatitis C infection according to the ethnicity of the participants. 
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Table 5: Risk factors for hepatitis C infection according to ethnicity of the 
participants.  
 New Zealand 
European 
% (n = 151) 
Other 
European 
% (n = 35) 
Maori 
%(n = 23) 
Others  
% (n = 9) 
IV drug use 5.3 % (8) 5.7 % (2) 4.3 % (1) 0 % (0) 
HCV antibody positive 
mother 
0.7 % (1) 0 % (0) 0 % (0) 0 % (0) 
HIV Infection 0.7 % (1) 0 % (0) 0 % (0) 0 % (0) 
Blood/organ 
recipient before 1990 
3.3 % (5) 8.6 % (3) 0 % (0) 0 % (0) 
Haemodialysis 0 % (0) 2.9 % (1) 0 % (0) 0 % (0) 
Blood/organ 
recipient overseas* 
0 % (0) 5.7 % (2) 0 % (0) 0 % (0) 
Procedure overseas* 7.3 % (11) 34.3 % (12) 4.3 % (1) 22.2 % (2) 




38.7 % (58) 17.1 % (6) 56.5 % (13) 22.2 % (2) 
Barber/nail salon 49 % (74) 48.6 % (17) 34.8 % (8) 88.9 % (8) 
Needle stick injury 11.3 % (17) 11.4 % (4) 0 % (0) 11.1 % (1) 
Administered first aid 
to an unknown 
bleeding person 
19.9 % (30) 25.7 % (9) 17.4 % (4) 11.1 % (1) 
% within ethnicity. *Blood/organ recipient and procedures done overseas excluding 




4.4 Knowledge of Study Participants Regarding Hepatitis B and C 
 
4.4.1 Knowledge of transmission of Hepatitis B and C  
 
Two hundred and eight (95.4%) of the study participants reported that hepatitis B 
and C can be transmitted by sharing IV drug utensils. Similarly a majority of the 
study participants were aware that hepatitis B and C can be spread via unsterile 
procedures and exposure to blood in the workplace – 91.3% and 83.5% 
respectively. Eighty three (38.1%) of the participants were not aware that hepatitis 
B and C can be spread by sharing a tooth brush or a razor. Participants’ knowledge 





Figure 6: Number of participants who reported that hepatitis B and C can be 




4.4.2 Knowledge regarding treatment of Hepatitis B and C 
 
Participant’s knowledge regarding availability of treatment for hepatitis B 
and C was assessed. Ninety one out of 218 (41.7%) study participants reported that 
hepatitis B can be treated; 22 (10.1%) responded that there was no treatment 
available and 102 (46.8%) reported that they ‘don’t know’.  Three participants 
provided no response to this question. 
One hundred and twenty nine participants (59.2%) reported that treatment 
is available for hepatitis C. Seventeen (7.8%) reported that no treatment was 
available and 70 (32.1%) did not know the answer. Two participants provided no 
response to this question. 
Knowledge regarding funding for hepatitis C treatment was assessed and 
102 (46.8%) reported that funding is available for hepatitis C treatment. More than 
half of the study participants were either not aware (49.5%) or did not believe 
funded treatment was available (3.7%).  
Participants were asked who they would approach to get treatment. One 
hundred and seventy four (79.8%) responded that they would approach their 
general practitioner for treatment. Twenty nine (13.3%) and 15 (6.9%) participants 
reported that they would approach an infectious disease specialist and a 
gastroenterologist for treatment respectively. 
 
4.4.3 Knowledge regarding vaccination of Hepatitis B and C 
 
Participants’ knowledge regarding vaccination for hepatitis B and C was also 
assessed. More than half of the participants were aware that vaccination for 
hepatitis B was available. However 39% (85 participants) did not know the answer 
to this question and 13 (6%) did not believe there was any vaccine available for 
hepatitis B.  Only 47 participants (21.6%) were aware that there was no vaccine 
available for hepatitis C. Ninety nine (45.4%) responded that they ‘don’t know’ and 




4.4.4 Response of Participants to Knowledge Based Questions 
 
 The knowledge of study participants was assessed regarding hepatitis B and 
C with 12 questions in the questionnaire. The study population scored 58.7% on 
average in the knowledge based questions. The median was 58.3% with an 
interquartile range of 50 to 75. The number of participants who provided correct 
answers to knowledge based questions is given in table 6. A substantial proportion 
(more than 38%) of study participants were not aware that hepatitis B and C can be 
transmitted by sharing a toothbrush or razor.  Sixty-eight (31.2%) of the study 
population were not aware that hepatitis B and C can be spread through sexual 
intercourse. Similarly 28.2% were not aware that hepatitis B and C can be 
transmitted from a mother to baby at birth. More than half of the study participants 
(59.2%) were aware that treatment for hepatitis C is available. However 32.1% 




Table 6: Study participants who provided correct answers to knowledge 
based questions. 
 
Question Percent correct 
answers  
How are hepatitis B & C spread?  
    -sharing a toothbrush or razor 61.9% (n = 135) 
    -sharing IV drug utensils (needles/spoons) 95.4% (n = 208) 
    -through sexual intercourse 68.8% (n = 150) 
    -from mother to baby at birth 71.6% (n = 156) 
    -unsterile medical/dental/cosmetic procedures   
(tattoos, piercings) 
91.3% (n = 199) 
    -occupational hazards (blood exposure in workplace) 83.5% (n = 182) 
Can hepatitis be treated?  
    -hepatitis B 41.7% (n = 91) 
    -hepatitis C 59.2% (n = 129) 
Can you be vaccinated against hepatitis B? (yes) 55% (n = 120) 
Can you be vaccinated against hepatitis C? (no) 21.6% (n = 47) 
Is treatment for hepatitis funded in New Zealand? 46.8% (n = 102) 
How common is viral hepatitis in New Zealand? 11% (n = 24)* 
*Options of 5%, 10%, 20% and 50% were selected by 24%, 27.8%, 23.6% and 
13.4% participants respectively.  
 
Data are mean (M) ± standard deviation (SD), unless otherwise stated. There 
were 96 male and 122 female participants. The mean percentage of correct answers 
for males (60.07 ± 19.87) was higher than that of females (57.71 ± 16.64). There 
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was homogeneity of variances for percentage of correct answers for males and 
females, as assessed by Levene's test for equality of variances (p = 0.078). There 
was no statistically significant difference in percentage of correct answers between 
males and females, M = 2.35, 95% CI [-2.52 to 7.22], t(216) = 0.951, p = 0.343. 
A one-way ANOVA was conducted to determine if the percentage of correct 
answers was different for participants of different ethnicities. There was 
homogeneity of variances, as assessed by Levene's test for equality of variances (p = 
0.470). The mean percentage of correct answers for knowledge based questions 
decreased from New Zealand Europeans (n = 151, M = 59.60, SD = 17.71), to Other 
Europeans (n = 35, M = 60.00, SD = 20.30), to Maori (n = 23, M = 53.99, SD = 17.38), 
and to those of Asian ethnicity (n = 7, M = 51.20, SD = 20.09) (Figure 7). However, 
there were no statistically significant differences in percentage of correct answers 
for knowledge based questions between participants of different ethnicities, F(4, 
213) = 0.857, p =0.491. 
 
Figure 7: Percentage of correct answers for knowledge based questions for 




A one-way ANOVA was conducted to determine if the percentage of correct 
answers were different for participants with different levels of education. There was 
homogeneity of variances, as assessed by Levene's test for equality of variances (p = 
0.511). The mean percentage of correct answers for knowledge based questions 
decreased from those with undergraduate education (n = 94, M = 62.15, SD = 17.70), 
to those with secondary education (n = 27, M = 56.17, SD = 21.11), to graduates (n = 
23, M = 56.16, SD = 16.13), and to those with tertiary education (n = 72, M = 55.67, 
SD = 17.74) (Figure 8). However, there were no statistically significant differences 
in percentage of correct answers for knowledge based questions between 
participants with different levels of education, F(4, 213) = 0.857, p =0.491. 
 
 
Figure 8:  Percentage of correct answers for knowledge based questions by 
participants according to their level of education. 
 
4.5  Participants’ Perceived Prevalence of Hepatitis C 
  
Participants’ knowledge regarding the prevalence of hepatitis B and C was 
assessed.  A large proportion of the participants over-estimated the prevalence of 
hepatitis in New Zealand. One hundred and forty participants (64.2%) reported the 
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prevalence to be 10% or higher. 24% reported the prevalence to be 5% and 11% 
reported the prevalence to be 1%. 
 
4.6 Experience of Participants with Rapid Point-of-care Test 
 
 One hundred and eleven (50.9%) of the participants had the mouth swab test 
and 107 (49.1%) had the finger prick point-of-care test. The number of male 
participants who had the mouth swab and finger prick tests were 47 (42.3%) and 
49 (45.8%) respectively. The median age + SD of participants who had the mouth 
swab test was 34 + 17.6 years and that of those who had the finger prick test was 27 
+ 13.5 years. 
 
4.6.1 Reason for choosing a rapid point-of-care test 
A majority of participants (n = 131, 60.1%) reported that they would choose 
the rapid point-of-care test because they prefer fast results. A substantial 
proportion of participants (n = 67, 30.7%) reported that they would choose the test 
because it was not painful. Seventeen of these participants (out of 67) had the finger 
prick point-of-care test.  
 
4.6.2 Recommending the rapid point-of-care test to a friend or family member 
 Two hundred and eleven (96.8%) of the participants reported that they 
would recommend the rapid point-of-care test to their friend or family member.  
Only 7 participants reported that they would not recommend the test to their friend 
of family member. Five of these participants had the finger-prick point-of-care test.  
 
4.6.3 Timing of test results and anxiety associated with testing 
A majority of study participants (n = 204, 93.6%) reported that they 
preferred to get their results on the same day instead of waiting. A majority of 
participants (n =163, 74.8%) reported that the rapid point-of-care test caused less 
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anxiety compared to a usual blood test (via venepuncture and waiting for results). 
Some (n = 49, 22.5%) reported that it made no difference while others (n = 6, 2.8%) 
did not agree that it caused less anxiety.  
 
4.6.4 Perception regarding reliability and ease of rapid point-of-care test 
Regarding a statement whether the rapid point-of-care test was as reliable as 
a usual blood test, 69 (31.7%) agreed, 21 (9.6%) disagreed and 128 (58.7%) 
reported that they ‘don’t know’. A majority of participants (n = 201, 92.2%) agreed 
that the point-of-care test was easier than a usual blood test. One participant who 
had the mouth swab test disagreed with this. Fifteen (6.9%) participants reported 
that it made no difference.  
 
4.6.5 Information provided about rapid point-of-care test and understanding of result 
 Two hundred and fifteen (98.6%) participants reported that they were given 
adequate information about the rapid point-of-care test. All participants who 
answered the question regarding understanding their result responded in 
affirmative (n = 217). One participant did not respond to this query in the 
questionnaire.  
47 
CHAPTER FIVE:  DISCUSSION  
 
An estimated 1% of the world’s population (more than 70 million people) 
are chronically infected with HCV(1, 2). Chronic HCV and associated complications 
caused more than 500,000 deaths worldwide in 2015 alone(99). Chronic HCV 
infection contributes to 27% of cirrhosis and 25% of hepatocellular carcinoma in 
addition to other complications. It has been estimated that more than 50,000 people 
in New Zealand are infected with hepatitis C with approximately 1000 new cases 
each year(13). At least 50% or more of these patients are currently undiagnosed. 
Chronic hepatitis C infection causing liver cirrhosis and hepatocellular carcinoma is 
currently the chief indication of  liver transplantation in New Zealand(64).  
 
A majority of the participants in the study preferred the rapid point-of-care 
test over the usual blood test via venepuncture. Previous studies have also 
demonstrated the feasibility and preference for rapid point-of-care testing for 
hepatitis C.  A previous study has noted that rapid testing for hepatitis C was 
preferred by 82.9% of participants over venepuncture in their cohort of high risk 
participants comprising people who inject drugs (PWID)(100). Among PWID 
venous access can be difficult due to a history of multiple intravenous injections 
with associated thrombophlebitis and venous sepsis resulting in chronic damage to 
and difficulty accessing peripheral veins for venepuncture. One of the main reasons 
of preference for point-of-care tests in this cohort at high risk of hepatitis C is 
venous access difficulties with venepuncture tests(82). 
 
Participants in this study who had the mouth swab test as well as those who 
had the finger-prick test preferred the rapid point-of-care test and reported that it 
caused less anxiety, was easier and they would recommend it to their family or 
friends. Oral fluid, finger-prick and venepuncture based tests for hepatitis C have 
been compared in a cross-sectional study among PWID and there was a clear 
preference for oral fluid based tests with females reporting a higher preference 
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(65%) compared to males (49%)(101). We did not directly compare these different 
modalities of administration in the same participants in this study; however those 
getting the finger-prick test still preferred it over the usual blood test via 
venepuncture.  
 
A significant proportion (36.2%) of participants reported getting a tattoo or 
a body piercing at a place in possible unsterile conditions. It is known that young 
adults are currently more likely to have a tattoo than the general population(102). 
Recent data has shown that nowadays tattooed persons do not have a lower 
education, riskier lifestyle and a higher rate of drug abuse compared to the general 
population(102, 103). However getting a tattoo in unsterile conditions can lead to 
transmission of hepatitis C among other viral/bacterial diseases as well as increase 
the risk of complications secondary to the tattooing procedure(104). The 
proportion of participants in this study getting a tattoo or a body piercing at a place 
in unsterile conditions is certainly concerning. This could result in an even more 
significant problem if the prevalence of hepatitis C in New Zealand was higher 
however the risk of an outbreak from such practise remains(105, 106). 
 
Almost half of the participants (49.1%) reported getting service at a barber 
or nail salon in possible unhygienic or unsterile conditions. Bacteria as well as blood 
borne viruses can be transmitted to or from operators and clients at a barbershop 
and nail salon via cuts in the skin or open wounds and sores as well as by the use of 
equipment that is not disinfected or unsterilized(106, 107). In 2018, a regional 
public health survey of nail salons in Wellington region of New Zealand found no 
formal qualifications of the staff in more than half of the nail salons visited(108) 
[Regional Public Health Survey 2018). There was limited understanding of 
transmission of blood borne infections including blood borne viruses. The same 
survey found that a substantial number (60%) would continue treatment even if 
there was bleeding in the treatment area and only 64% of salons would recommend 
that treatment should be deferred due to an infection in the area (hand/foot) of 
treatment. However, it was observed that there was considerable support from the 
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study participants (93%) regarding some form of regulations to improve industry 
standards.  
 
The lack of knowledge regarding the risk factors, transmission and treatment 
of chronic viral hepatitis is high among the participants of this study. More than 
38% of participants were not aware that chronic viral hepatitis can be spread by 
sharing a toothbrush or a razor with an infected person. This was the most 
unknown risk factor for transmission among the study participants. This is in line 
with findings of a previous study among middle-aged adults in Dunedin, New 
Zealand from 2015(70). Additionally, 28% of study participants were not aware 
that hepatitis B and C can be transmitted from mother to baby at birth. More than 
40% of participants were not aware of any treatment availability for hepatitis C. 
Regarding public funding for hepatitis C treatment, more than half of the study 
participants were either not aware or did not believe funded treatment was 
available in New Zealand. These findings can have significant consequence for 
future patient education and community awareness programs. Formal education 
and raising awareness of Hepatitis C will assist in increased testing and 
identification of persons with hepatitis C infection as well as improve care 
coordination(109-111). 
 
Fourteen out of 15 positive tests in this study were false positives. All of 
these were done via the mouth swab method. Studies of OraQuick HCV point-of-care 
test using a mouth swab have reported a specificity of 99 to 100% (112, 113). 
Although increase in false negative rate with the OraQuick test has been reported in 
HIV positive patients (114). This association of HIV positivity has not been shown 
with false positive tests using OraQuick mouth swab test. The reason for the high 
number of false positive cases in our study is not clear. The required wait period for 
mouth swab test after food and beverage as well as after oral care product use was 
implemented when needed in this study. Previous studies have reported false 
results of point-of-care testing to be associated with female sex (97, 115). The cause 
for this is unclear and the reported numbers are small. We did not find such an 
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association in this study as 6 participants with false positive tests were male and 8 
were females. 
 
The reported prevalence of chronic hepatitis C in New Zealand varies 
depending on the groups assessed. The prevalence in the general population is 
believed to be 1.28%(71). In New Zealand, the prevalence of hepatitis C antibody 
positivity has been reported to be 0.3% in a prevalence study done in Christchurch 
using an electoral role (69). The prevalence of hepatitis C antibodies in those aged 
forty to fifty-nine years has been reported to be 4.01% among people living in 
Dunedin (70). Our study had a relatively small number of participants but we 
expected a higher number of positive tests due to the inclusion criteria and the 
proportion of participants reporting risk factors. However the results showed only 
one active HCV infection out of 218 tested. It is assumed that the prevalence of 
hepatitis C in the general population in New Zealand is the same as Australia (71), it 
is possible that this could be an overestimate. The limited locality and number of 
participants in this study however may have resulted in underestimation of the 
prevalence.  It is possible that there may be a selection bias for the participants 
enrolled in this study. Participants were enrolled in the study at general practise 
clinics and at a sexual health clinic. Hence the participants were those who were 
engaged with health care services. It is known that groups at high risk of hepatitis C 
can have difficulties in engaging with health care services(116, 117). Therefore the 
participants in the study could be at lower risk at baseline.  
 
To the astute and experienced clinical specialist, the diagnosis and treatment 
of chronic hepatitis C may seem straight forward with the introduction of new 
DAAs. However there are multiple steps involved in the current approach to making 
a diagnosis and initiating treatment (Figure 1). This also involves multiple 
appointments for the patient as well as multiple interactions and visits to the 
laboratory or a collection centre to see the phlebotomist for blood tests(76, 79). 
Hence in the journey that a patient takes in this process there are multiple points 
where a loss to follow up can occur. The patient also has to make multiple 
appointments, possibly take time off work and arrange to get to the appointments 
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and testing centres. As noted a majority of patients with chronic hepatitis C are 
asymptomatic and they may have less motivation of going through this process. A 
similar trend has been noted in patients with HIV with asymptomatic patients 
frequently reporting that they “currently do not need” HIV care(118). In addition 
symptoms due to disease and a general poor health were frequent motivators for 
seeking help and treatment.  
 
The currently used point-of-care tests for HCV are based on detection of HCV 
antibodies. Integration of these tests into the care cascade will decrease the steps 
required to initiate treatment and lower the burden of multiple visits and 
appointments for the patient leading to improvement in linkage of care (Figure 9). 
Research is currently on-going regarding straight testing for HCV RNA to directly 
identify patients with active infection without the need for HCV antibody testing. 
Such prototype tests use automated reverse transcriptase polymerase chain 
reaction with fluorescence to quantify HCV RNA. The challenges to using  such a test 
include the need for a trained technician, a waiting time of an hour or more to run 
the test and a less sensitive lower limit of quantification (100IU/ml for Xpert HCV 
Viral Load; Cepheid, Sunnyvale) compared to traditional HCV RNA PCR testing(119, 
120). Of 205 participants tested in one study with this finger-prick test for HCV 
RNA, 8% had no valid result either due to out of range internal control or low 
sample volume(120). However it would be logical to assume that this process will 
improve significantly in the coming years or sooner and the only possible limiting 
factors to widespread implementation could be the cost and technical expertise 
needed on-site compared to point-of-care antibody testing. The potential benefit of 
a cost-effective HCV RNA point-of-care test would be substantial and could result in 
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Figure 9: HCV care cascade and steps leading to treatment using HCV antibody point-of-care test. Points of potential loss to 
follow-up due to patient factors are indicated by red triangles (compare to figure 1 showing current approach). HCV: Hepatitis C. 
PCR: Polymerase chain reaction. RNA: ribonucleic acid. 
 
At the initial appointment HCV antibody POC test is administered. Results are discussed in 
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Figure 10: Potential future HCV care cascade and steps leading to treatment using HCV RNA point-of-care test. Points of 
potential loss to follow-up due to patient factors are indicated by red triangles (compare to figure 1 showing current approach). 
HCV: Hepatitis C. PCR: Polymerase chain reaction. POC: point-of-care. RNA: ribonucleic acid. 
Future HCV RNA PCR point-of-care test resulting in testing, 
diagnosis and treatment initiation in the same visit 
bypassing multiple steps in the current HCV care cascade.  
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Indigenous peoples in New Zealand (Māori) overall have poorer health 
related outcomes(121). They also have a greater burden of both non-communicable 
and communicable diseases when compared with the general population. The 
higher prevalence of factors promoting liver fibrosis and neoplastic transformation 
in the liver among this population include type 2 diabetes and other components of 
the metabolic syndrome(122). These factors increase the risk of steatohepatitis, 
advanced liver fibrosis, cirrhosis and associated complications including 
hepatocellular carcinoma. Those with hepatitis C infection in this population would 
thus be at a higher risk of liver fibrosis, cirrhosis and associated complications. In 
this study we found a statistically significant association between Māori ethnicity 
and a history of getting a tattoo or piercing with unsterilized equipment as reported 
by the study participants. As using unsterilized equipment for tattoos is a known 
risk factor for hepatitis C infection, this could potentially increase the risk of 
infection in indigenous peoples. Raising awareness among everyone about this risk 
factor and its potential to result in hepatitis C outbreaks is important.  New Zealand 
also has immigrants from the Asia–Pacific region where the prevalence of viral 
hepatitis is high(123).  
 
Aiming to accomplish the WHO hepatitis C elimination targets by 2030 
would require that a very significant proportion of those with hepatitis C need not 
only be diagnosed but also linked to appropriate care and treated successfully. A 
point-of-care test in the treatment cascade of hepatitis C can simplify the process 
and decrease the number of people lost to follow-up(93-96). We demonstrated that 
both oral swab and finger-prick point-of-care testing for hepatitis C in the primary 
care setting as well as in a sexual health clinic is feasible and easily administered. It 
demonstrates that diagnostic testing in the care cascade of hepatitis C can be made 
efficient and reduce the number of engagements with patients which in turn 
decreases the potential of losing the patient to follow-up. This study provides useful 
data to guide implementation of rapid point-of-care testing of hepatitis C in selected 
settings in New Zealand as a strategy to boost the identification of those with 




Compared to general practise settings, high prevalence settings like needle 
exchange programs, prisons and alcohol/drug treatment centres are likely to 
provide more opportunity for identification of those with hepatitis C infection with 
a point-of-care test. This will improve linkage to care and the opportunity of 
treatment with DAAs which have a high rate of cure. The caveat is that those 
infected with hepatitis C due to an exposure in the distant past, no on-going high 
risk behaviours and no regular engagement with health care services may be missed 
as chronic hepatitis C infection is asymptomatic in a majority of patients until 
progression to advanced liver disease and the development of associated symptoms. 
Increasing knowledge and awareness regarding hepatitis C in the community is thus 
important in improving the engagement of such persons with health care service. 
Implementing a rapid point-of-care test in the hepatitis C care cascade can make 




This is the first study of hepatitis C point-of-care testing in the general 
population in New Zealand. The study aimed to assess the feasibility of point-of-care 
HCV testing in general practice setting and at a sexual health clinic in Dunedin, New 
Zealand. The study also provided information regarding the experience of 
participants with this point-of-care test. This study demonstrated that point-of-care 
testing using mouth swab and finger-prick testing is acceptable and participants 
reported a preference for rapid testing over traditional venepuncture based tests. 
However there were a number of false positives with the mouth swab method of 
testing. Knowledge regarding transmission, treatment and prevalence of hepatitis C 
was low. This study has also provided valuable insights into the viability and 
participants’ experience with both mouth swab and finger-prick point-of-care 
testing for HCV in New Zealand. The results can form the basis for a larger trial with 
multiple sites across the country and a higher number of participants. However 
testing via mouth swab should be done with caution and directly compared with 
other methods of testing due to the findings in this study. Additionally in New 
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Zealand setting it may be more suitable to do point-of-care testing for HCV in high 
prevalence settings like needle-exchange programs. The funding and availability of 
pangenotypic DAA therapy for hepatitis C will continue to improve access to HCV 
treatment in New Zealand. The challenge of identification and linkage to care of 
those with undiagnosed chronic HCV remains and in addition to raising awareness, 
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Rapid Point-of-care Test for Hepatitis C
Questionnaire
Please tick the box corresponding to your answer or fill in the blank space.
Age: yrs. Sex:            Male         Female
Ethnicity: Country of birth:  
1.      Yes No   D o  you have a history of intravenous (injecting) drug use?
 
YesNo    Were you born to an HCV positive mother?
YesNo    Do you have human immunodeficiency virus (HIV) infection?
YesNo    Have you received blood products or organ(s) before 1990?
YesNo    Have you ever been on haemodialysis?
YesNo    Have you received blood products or organs overseas (excluding                    
Canada, United States, Western Europe and Australia)?
YesNo     Have you had any surgical or dental procedures overseas (excluding 
Canada, United States, Western Europe and Australia)?
YesNo     Have you ever been in prison?
YesNo     Have you ever had any tattoo, piercing or used piercing equipment 
that may have been unsterilized?
YesNo     Have you ever visited a barber, beauty therapist or nail salon in unsterile 
conditions?
YesNo     Have you ever had a needle stick injury?
  Yes No    Have you ever given first aid to a bleeding person who is unknown to 
you?
2. How do you think Hepatitis B and C are spread? (You may select more than one option)
□Sharing a toothbrush or razor with an infected person
□Sharing needles, spoons, filters (IV drug utensils)
□Through sexual intercourse
□From mother to baby at birth
□Unsterile medical / dental / cosmetic procedures (tattoos/piercings)
□Contact sport
□Occupational hazards (exposure to blood in the work place)
□Other __________________________________________
3. Can viral hepatitis be treated?    Hepatitis B:     Yes  No    □Don’t know
   Hepatitis C:Yes  No    □Don’t know
4. Can you be vaccinated against:    Hepatitis B?       Yes   No    □Don’t know 
 Hepatitis C?      Yes                 No        □Don’t know
5.How common do you think hepatitis is in New Zealand?
□1% □5% □10% □20% □50%
Other: _____________________
6.Is treatment for Hepatitis funded in New Zealand? □Yes □No       □Don’t know
7.Who would you approach to get treatment?
GP         Gastroenterology Specialist           Infectious Disease Specialist
8. Your highest Level of education:
        □Secondary  □Tertiary □Undergraduate degree □Graduate
 9.   How often do you see your GP?
□Weekly □Monthly □6 Monthly        □Yearly              □5 Yearly        □Rarely
10. Have you ever received a blood transfusion?  □Yes   □No,       
               If yes, in what year and country? ___________________________
  11. Do you have a tattoo?          □Yes    □No     
         If yes, obtained in what country? ______________________________
  12.  Do you have a body piercing?   □Yes    □No    
                    If yes, obtained in what country? ______________________________
13.  Have you had a ritual event involving circumcision or scarification?     □Yes    □No    
                  If yes, obtained in what country? _______________________________
14.  Have you shared common bathroom items such as toothbrushes or razor blades? □Yes    
□No
15.   Is/has your mother been an injection drug user?    □Yes    □No
16.  Has your mother had hepatitis B?  □Yes    □No,      Hepatitis C?   □Yes    □No   □Don’t 
know
  17.  Have you been vaccinated for Hepatitis B?     □Yes    □No   □  Don’t know
18.  What would be your main reason for choosing this rapid test for hepatitis C?
 I prefer fast results.
 This test is not painful.
 I am afraid of blood draws.
 This test is newer.
 This test is less stressful.
 I have bad veins for blood tests
 This is the first time I have been offered testing for HCV
19.  Would you recommend this rapid test to a friend or a family member?
Yes No
20.  I prefer getting my test results on the same day.       Agree Disagree
21. It would have been better to wait a few days for the test result.Agree Disagree
22. The rapid test caused less anxiety than a blood test.  Agree  Disagree No 
difference
23. The rapid test is as reliable as a blood test.  Agree Disagree Don’t know
24. The rapid test was easier than a usual blood test.  Agree  Disagree No difference
25. I was given adequate information before the test.     Agree         Disagree
26. I understand my test results.                 Agree Disagree
27. Would you prefer this rapid test instead of the usual blood test done at your GP 
or at the laboratory?    Yes        No

